Inoperable RCC: stereotactic ablative body radiotherapy shows promise
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Stereotactic ablative body radiotherapy (SABR) delivered encouraging cancer control, functional preservation and early survival outcomes in patients with small and large primary inoperable renal cell carcinoma (RCC).
Treatment was well tolerated.
Why this matters
Age and comorbidities preclude some patients from surgical resection.
Nonsurgical definitive treatment options are limited.
SABR is a well-established noninvasive option for lung, liver, and spinal cancers.
There is a paucity of prospective data to support routine adoption of SABR for primary inoperable RCC.
These findings also suggest baseline neutrophil to lymphocyte (N/L) ratio may predict response in RCC.
Study evaluated SABR in 37 inoperable patients with RCC.
For primary RCC <5 cm, 26 Gy, and for RCC ≥5 cm, 42 Gy in 3 fractions was delivered.
Funding: CASS Science and Medicine Grant; Royal Au...